A Safety and Efficacy Study for Alzheimer's Disease (Prodromal AD)

Registry ID
EUCTR2012-005542-38
Source registry
EUCTR
Status
Prematurely Ended
Phase
PHASE3
Sponsor
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Start date
2014-02-12
Completion date
2018-04-17
Last update
2026-08-16

Conditions

Summary

• To assess the efficacy of two doses of MK-8931 based on overall clinical progression in subjects with prodromal Alzheimer's Disease (AD). • To assess the safety and tolerability of two doses of MK-8931 in the treatment of subjects with prodromal AD.

Locations

View on source registry